AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)
The only known investigational therapy for SBMA in Phase 3 development worldwide AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) Following submission of the...
Covered in this story
Call it yourself
No calls on $ROMA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Roma Green Finance →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.